More Than 2,000 Patients Already Using Merck’s Keytruda
This article was originally published in The Pink Sheet Daily
Executive Summary
The immunotherapy is getting a strong reception from melanoma patients, but is behind Bristol’s Opdivo in the lung cancer setting.